Genocea Biosciences Inc (NASDAQ:GNCA) has earned an average rating of “Buy” from the six analysts that are currently covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $4.00.
Several analysts recently commented on the stock. HC Wainwright set a $5.00 price target on shares of Genocea Biosciences and gave the stock a “buy” rating in a report on Wednesday, November 7th. Zacks Investment Research upgraded shares of Genocea Biosciences from a “hold” rating to a “buy” rating and set a $0.75 price target for the company in a report on Monday, November 5th.
Shares of GNCA opened at $0.57 on Friday. Genocea Biosciences has a one year low of $0.49 and a one year high of $1.39. The stock has a market capitalization of $49.38 million, a price-to-earnings ratio of -0.29 and a beta of 1.14. The company has a quick ratio of 4.01, a current ratio of 4.01 and a debt-to-equity ratio of 1.91.
Hedge funds have recently bought and sold shares of the stock. BlackRock Inc. boosted its holdings in shares of Genocea Biosciences by 169.1% during the first quarter. BlackRock Inc. now owns 3,960,353 shares of the biotechnology company’s stock worth $4,159,000 after purchasing an additional 2,488,540 shares during the period. Paloma Partners Management Co acquired a new stake in shares of Genocea Biosciences during the second quarter worth approximately $343,000. California State Teachers Retirement System boosted its holdings in shares of Genocea Biosciences by 166.6% during the first quarter. California State Teachers Retirement System now owns 125,569 shares of the biotechnology company’s stock worth $132,000 after purchasing an additional 78,469 shares during the period. DRW Securities LLC acquired a new stake in shares of Genocea Biosciences during the second quarter worth approximately $205,000. Finally, Fosun International Ltd acquired a new stake in shares of Genocea Biosciences during the third quarter worth approximately $323,000. Institutional investors and hedge funds own 60.86% of the company’s stock.
Genocea Biosciences Company Profile
Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer vaccines. The company uses its proprietary discovery platform, ATLAS, to recall a patient's pre-existing CD4+ and CD8+ T cell immune responses to tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses.
Featured Article: Price to Earnings Ratio (PE)
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.